Zeo ScientifiXZEOX +7.34%56 PS Ratio is 1.91 as of Jul. 06, 2026, which is 54% below its 10-year median of 4.12. GuruFocus rates ZEOX with a GF Score™ of 56/100 and a GF Value™ of $2.67 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 929 Biotechnology companies, Zeo ScientifiX ranks better than 86.01% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Zeo ScientifiX's share price is $1.90.
Zeo ScientifiX's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 was $1.00. Hence, Zeo ScientifiX's PS Ratio for today is 1.91.
The historical rank and industry rank for Zeo ScientifiX's PS Ratio or its related term are showing as below:
ZEOX'
s PS Ratio Range Over the Past 10 Years
Min: 0.77 Med: 4.12 Max: 105.05
Current: 1.91
During the past 13 years, Zeo ScientifiX's highest PS Ratio was 105.05. The lowest was 0.77. And the median was 4.12.
ZEOX's PS Ratio is ranked better than 86.01% of 929
companies
in the Biotechnology industry
Industry Median: 9.91
vs ZEOX: 1.91
Zeo ScientifiX Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Zeo ScientifiX was 39.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -10.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -6.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 8.60% per year.
During the past 13 years, Zeo ScientifiX's highest 3-Year average Revenue per Share Growth Rate was 47.60% per year. The lowest was -11.60% per year. And the median was 15.15% per year.
Back to Basics: PS Ratio
Zeo ScientifiX (OTCPK:ZEOX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Zeo ScientifiX PS Ratio Related Terms
Zeo ScientifiX PS Ratio Historical Data
* Premium members only.
The historical data trend for Zeo ScientifiX's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zeo ScientifiX's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zeo ScientifiX PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's PS Ratio distribution charts can be found below:
* The bar in red indicates where Zeo ScientifiX's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Zeo ScientifiX's Share Price of today is $1.90. Zeo ScientifiX's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Zeo ScientifiX (ZEOX) has a PS Ratio of 1.91 as of Jul. 06, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Zeo ScientifiX and its competitors. This is 54% below median its historical median of 4.12. Over the past decade, Zeo ScientifiX's PS Ratio has ranged from 0.77 to 105.05. According to the industry distribution chart, Zeo ScientifiX ranks #130 out of 929 companies in the Biotechnology industry, placing it in the top 14%.
Is Zeo ScientifiX's PS Ratio too high?
Zeo ScientifiX's current PS Ratio of 1.91 is 54% below median its 10-year median of 4.12. Over the past 10 years, this metric has ranged from a low of 0.77 to a high of 105.05. The Biotechnology industry median PS Ratio is 9.91. Zeo ScientifiX's value of 1.91 is 80.7% below this industry median. Based on the distribution chart, Zeo ScientifiX ranks #130 out of 929 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zeo ScientifiX has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zeo ScientifiX's PS Ratio compare to JUNS and HOOK?
According to the Biotechnology industry distribution chart, Zeo ScientifiX ranks #130 out of 929 companies for PS Ratio. This places Zeo ScientifiX in the top 14% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.91. Zeo ScientifiX's value of 1.91 is 80.7% below this benchmark. Historically, Zeo ScientifiX's own PS Ratio has ranged from 0.77 to 105.05 over the past decade. While the company's 10-year median is 4.12 vs. the industry median of 9.91, Zeo ScientifiX has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.91, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zeo ScientifiX's current PS Ratio of 1.91 is 80.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Zeo ScientifiX and its competitors. For the Biotechnology industry, the median PS Ratio is 9.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zeo ScientifiX's current PS Ratio is 1.91, which is 54% below median its own 10-year median of 4.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zeo ScientifiX stock overvalued right now?
Based on GuruFocus' analysis, Zeo ScientifiX (ZEOX) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.67, compared to a current price of $1.90 — trading 28.8% below its estimated fair value. The current PS Ratio is 1.91, which is 54% below median its 10-year median of 4.12 and 80.7% below the Biotechnology industry median of 9.91. Zeo ScientifiX's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Zeo ScientifiX (ZEOX), the current PS Ratio is 1.91 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zeo ScientifiX (ZEOX) Overvalued in 2026?
Based on GuruFocus' analysis, Zeo ScientifiX stock appears to be undervalued.
The current stock price of $1.90 is trading 28.8% below its estimated GF Value™ of $2.67.
GuruFocus considers Zeo ScientifiX to be Modestly Undervalued.
Key valuation signals for ZEOX:
PS Ratio: 1.91 (54% below median its 10-year median of 4.12)
GF Value™: $2.67 vs. price of $1.90 (28.8% below fair value)
Industry Position: 80.7% below the Biotechnology median (#130 of 929)
No single metric tells the full story. See the ZEOX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zeo ScientifiX Inc is a clinical-stage biopharmaceutical company located inside Nova Southeastern University's Collaborative Center for Research in Davie, Florida. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company's proprietary products, including Zofin, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X (PPX ), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood (RAAM Products).
56GF Score
Get the complete analysis for ZEOX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZEOX has been successfully added to your 
